Latest pharma news

Feb 16, 2018

Vertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko's annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaf...

Feb 06, 2018

Charles River to fuel hit discovery with AstraZeneca high-throughput collaboration After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC) with the help of highly advance AstraZeneca technology. Now the company is able to offer the ...

Jan 25, 2018

Pharma startup Bonti has recently grabbed a funding of USD 15 million Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C, The Company is focused on developing a new botulinum neurotoxin for both therapeutic and cosmetic uses. Funding will help in the...

Jan 19, 2018

Pandion Therapeutics bags USD 58 million in series A Funding Focused on developing Targeted immune modulator drugs, Pandion Therapeutics has successfully grabbed USD 58 million in series A funding. The company is led by highly experienced professionals. Anthony Coyle (former senior vice president at Pfizer and globa...

Jan 12, 2018

Adapsyn signed a USD 162 million deal with Pfizer for microbe-mining project Adapsyn has recently signed a deal with Pfizer for the microbe-mining with the help of advance platform developed by the Canadian company adapsyn. The technique offers a quick filter for promising candidates with better efficacy. Due to the...

Jan 05, 2018

Centrexion Therapeutics has raised a total of USD 67 million to fund phase 3 pain trial Jeffrey Kindler‘s managed biotech company Centrexion Therapeutics has raised $67 million. The funds will be used to promote nonopioid pain drug candidate CNTX-4975 into a phase 3 trial with patients suffering from knee osteoarth...

Dec 19, 2017

Regeneron/Sanofi’s PD-1 drug candidate will be tested with ISA’s HPV immunotherapy Regeneron and Sanofi’s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma’s human papillomavirus (HPV) targeting drug for testing. The new drug is competing to become the sixth PD-1/PD-L1 drug on the market. Joined with...

Nov 28, 2017

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...

Feb 21, 2017

USFDA warns Bengaluru-based Resonance Labs of manufacturing norms violations US health regulator USFDA has red-flagged significant deviations from manufacturing norms at the Bengaluru-based API facility of Resonance Laboratories, including failure to have adequate cleaning procedures to prevent contamination of prod...

Jan 31, 2017

AstraZeneca announces availability of Saxa / Dapa FDC in UK UK-based AstraZeneca has announced the availability of Qtern for adult patients with type 2 diabetes in the country. Quern is a fixed dose combination of saxagliptin and dapagliflozin. The tablet received marketing authorization from the European Commission...